Free Trial

Embecta (EMBC) Stock Price, News & Analysis

Embecta logo
$12.75 -0.11 (-0.88%)
As of 01:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Embecta Stock (NASDAQ:EMBC)

Key Stats

Today's Range
$12.66
$12.99
50-Day Range
$12.60
$20.10
52-Week Range
$9.93
$21.48
Volume
186,792 shs
Average Volume
422,539 shs
Market Capitalization
$741.03 million
P/E Ratio
12.72
Dividend Yield
4.71%
Price Target
$23.00
Consensus Rating
Moderate Buy

Company Overview

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Remove Ads

Embecta Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

EMBC MarketRank™: 

Embecta scored higher than 91% of companies evaluated by MarketBeat, and ranked 81st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Embecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Embecta has received no research coverage in the past 90 days.

  • Read more about Embecta's stock forecast and price target.
  • Earnings Growth

    Earnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Embecta is 12.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Embecta is 12.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.67.

  • Price to Earnings Growth Ratio

    Embecta has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.

  • Read more about Embecta's valuation and earnings.
  • Percentage of Shares Shorted

    4.17% of the float of Embecta has been sold short.
  • Short Interest Ratio / Days to Cover

    Embecta has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Embecta has recently increased by 35.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Embecta is a leading dividend payer. It pays a dividend yield of 4.40%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Embecta does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Embecta is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.

  • Read more about Embecta's dividend.
  • Percentage of Shares Shorted

    4.17% of the float of Embecta has been sold short.
  • Short Interest Ratio / Days to Cover

    Embecta has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Embecta has recently increased by 35.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Embecta has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Embecta this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for EMBC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Embecta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,778.00 in company stock.

  • Percentage Held by Insiders

    Only 0.42% of the stock of Embecta is held by insiders.

  • Percentage Held by Institutions

    93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Embecta's insider trading history.
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

EMBC Stock News Headlines

Embecta Insider Ups Holding By 20% During Year
DOGE could send 6 AI stocks through the roof
Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement from Elon any day now … Thousands of government jobs could be replaced … By a new form of AI. Recently perfected by Musk and his team at xAI.
See More Headlines

EMBC Stock Analysis - Frequently Asked Questions

Embecta's stock was trading at $20.65 on January 1st, 2025. Since then, EMBC stock has decreased by 38.5% and is now trading at $12.7050.
View the best growth stocks for 2025 here
.

Embecta Corp. (NASDAQ:EMBC) posted its earnings results on Thursday, February, 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative trailing twelve-month return on equity of 19.22%.

Embecta's top institutional shareholders include Vanguard Group Inc. (12.09%), Deerfield Management Company L.P. Series C (5.63%), American Century Companies Inc. (5.61%) and River Road Asset Management LLC (5.59%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann, David F Melcher and Milton Mayo Morris.
View institutional ownership trends
.

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
2/06/2025
Ex-Dividend for 3/14 Dividend
2/28/2025
Dividend Payable
3/14/2025
Today
3/25/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$26.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+78.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
12.86
Forward P/E Ratio
4.51
P/E Growth
0.78
Net Income
$78.30 million
Pretax Margin
2.64%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$2.98 per share
Price / Cash Flow
4.32
Book Value
($13.23) per share
Price / Book
-0.97

Miscellaneous

Free Float
57,890,000
Market Cap
$747.60 million
Optionable
Optionable
Beta
1.27
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:EMBC) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners